EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Ceroid lipofuscinosis type 2 disease: Effective presymptomatic therapy—Oldest case of a presymptomatic enzyme therapy

Delphine Breuillard, Lisa Ouss, Marie Thérèse Le Normand, Timothée de Saint Denis, Christine Barnerias, Matthieu P Robert, Monika Eisermann, Nathalie Boddaert, Catherine Caillaud, Nadia Bahi-Buisson, Isabelle Desguerre, Mélodie Aubart iD

European Journal of Neurology · 2024

DOI: 10.1111/ene.16324 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Delphine Breuillard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris Cité, Paris, Fran…. Hauptthemen laut MEDLINE: Neuronal Ceroid-Lipofuscinoses, Tripeptidyl-Peptidase 1, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Serine Proteases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare, lysosomal storage disorder that causes pediatric onset neurodegenerative disease. It is characterized by mutations in the TPP1 gene. Symptoms begin between 2 and 4 years of age with loss of previously acquired motor, cognitive, and language abilities. Cerliponase alfa, a recombinant human TPP1 enzyme, is the only approved therapy. We report the first presymptomatic cerliponase alfa intraventricular treatment in a familial case of CLN2 related to a classical TPP1 variant. Sister 1 presented with motor, cognitive, and language decline and progressive myoclonic epilepsy since the age of 3 years, evolved with severe diffuse encephalopathy, received no specific treatment, and died at 11 years. Sister 2 had a CLN2 presymptomatic diagnosis and has been treated with cerliponase since she was 12 months old. She is now 6 years 8 months and has no CLN2 symptom except one generalized seizure 1 year ago. No serious adverse event has occurred. Repeated Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition standardized index scores are heterogeneous in the extremely low to low average ranges. Mean length of utterances, a global index of sentence complexity, showed a delay, but a gradual improvement. The reported case enhances the major contribution of presymptomatic diagnosis and significant middle‐term treatment benefit for patients with CLN2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuronal Ceroid-LipofuscinosesTripeptidyl-Peptidase 1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesSerine ProteasesAminopeptidasesHumansFemaleRecombinant ProteinsChildEnzyme Therapy

Stichwörter der Autor:innen

CLN2TPP1case reportcerliponasepresymptomatic

Substanzen

Tripeptidyl-Peptidase 1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesTPP1 protein, humanSerine ProteasesAminopeptidasescerliponase alfaRecombinant Proteins

Autor:innen und Institutionen

  • Pediatric Neurology Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris Cité, Paris, France.
  • Child Psychiatry Department, Necker-Enfants Malades Hospital, AP-HP, Université de Paris Cité, Paris, France.
  • Pasteur Institute, Audition Institute, Inserm, Paris, France.
  • Psychopathology Laboratory, URP4057, Université de Paris Cité, Boulogne-Billancourt, France.
  • Pediatric Neurosurgery Department Necker-Enfants Malades Hospital, AP-HP, Université de Paris Cité, Paris, France.
  • Ophthalmology Department, Necker-Enfants Malades Hospital, AP-HP, Université de Paris Cité, Paris, France.

ORCID-Profile: Mélodie Aubart

Zitieren

APA

Breuillard, D., Ouss, L., Le Normand, M. T., Denis, T. S., Barnerias, C., Robert, M. P., Eisermann, M., Boddaert, N., Caillaud, C., Bahi-Buisson, N., Desguerre, I., & Aubart, M. (2024). Ceroid lipofuscinosis type 2 disease: Effective presymptomatic therapy—Oldest case of a presymptomatic enzyme therapy. European Journal of Neurology. https://doi.org/10.1111/ene.16324

Vancouver

Breuillard D, Ouss L, Le Normand MT, Denis TS, Barnerias C, Robert MP, et al. Ceroid lipofuscinosis type 2 disease: Effective presymptomatic therapy—Oldest case of a presymptomatic enzyme therapy. European Journal of Neurology. 2024. doi:10.1111/ene.16324

BibTeX
@article{Breuillard2024,
  author = {Breuillard, Delphine and Ouss, Lisa and Le Normand, Marie Thérèse and Denis, Timothée de Saint and Barnerias, Christine and Robert, Matthieu P and Eisermann, Monika and Boddaert, Nathalie and Caillaud, Catherine and Bahi-Buisson, Nadia and Desguerre, Isabelle and Aubart, Mélodie},
  title = {Ceroid lipofuscinosis type 2 disease: Effective presymptomatic therapy—Oldest case of a presymptomatic enzyme therapy},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16324}
}
Kostenlos starten →